MAIN CONTENT
A strategic mandate larger than a new title
The new management strategy office replaces and expands the future growth office previously headed by Shin. Its remit includes long-range planning, allocation of attention across businesses, portfolio adjustments, overseas opportunities and group-wide AI transformation. Reporting by The Korea Herald, The Korea Times and Yonhap places the change within Lotte's annual executive appointments for 2027. The office is therefore more than a ceremonial position: it is designed to influence where the conglomerate invests, which activities it reorganizes and how its affiliates modernize.
That broader assignment creates a measurable test of leadership. Investment decisions in biotechnology, consumer businesses and industrial operations will not necessarily pay off on the same timetable. AI initiatives, meanwhile, require changes to data, processes and worker skills, not merely technology announcements. Observers may read the appointment as a succession signal, but the immediate question for employees and investors is whether a centralized strategic vision can coexist with clear responsibility inside individual subsidiaries.
From finance to biotechnology and cross-border coordination
Born in 1986, Shin began his Lotte career in Japan in 2020 after working at Nomura Securities. His subsequent responsibilities extended across Japanese and Korean affiliates, including Lotte Financial, Lotte Chemical and Lotte Biologics.
















